Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACOVACT platform trial for experimental COVID-19 therapeutics
2020-001302-30Phase 2Terminated
- Sponsor
- Medical University of Vienna
- Start
- Apr 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of asunercept, Pentaglobin, lopinavir, ritonavir, rivaroxaban and 3 more in coronavirus disease 2019 (COVID-19) and viral pneumonia (7 arms), sponsored by Medical University of Vienna. Primary endpoint: Time to sustained improvement of one category from admission in the 7-point clinical performance scale. Started Apr 2020; status: terminated.
02
Drugs
asunerceptPentaglobinlopinavirritonavirrivaroxaban
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumonia
Beyond the preview
Go deeper on 2020-001302-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001302-30.